17.07.2024,
4911 Zeichen
Aachen, Germany (OTS) - Grünenthal, a leading pharmaceutical company
specializing in pain research and management, has announced
significant investments in its Latin American production sites. These
investments will enhance Grünenthal's production network, ensuring a
reliable supply of medicines for patients across Latin America,
Europe, and beyond.
Investment of more than €80 million to modernise Latin American production sites.\nIn Santiago de Chile, a 3,500-square-metre solids plant has been completely refurbished, creating a world-class manufacturing facility with a production capacity of 1.8 billion tablets annually.\nIn Quito, Ecuador, a new 1,800-square-metre plant will enable the production of 300 million high-quality tablets annually for pain patients in 17 European countries.\n Grünenthal operates a robust production network with five
manufacturing sites in Germany, Switzerland, Italy, Chile, and
Ecuador. These sites produce medicine from Grünenthal's portfolio and
offer contract manufacturing services to third parties. Grünenthal
recently invested over €80 million to enhance its production
capabilities in Latin America. To ensure production excellence and
expand the geographical reach of its Latin American facilities,
Grünenthal is implementing a standardized approach to product
robustness, quality, and regulatory compliance across all its global
manufacturing sites.
"Our investment in Latin America is a strong demonstration of our
commitment to long-term competitiveness in the region,” says Victor
Barbosa, Head of Global Operations and member of the Executive Board
Team. "Future-proofing our manufacturing capabilities underscores our
commitment to ensuring a safe, reliable, and efficient supply of
medicine to patients globally. Grünenthal delivers high-quality
medicine from Latin America to the world—a unique capability in the
region.“
Grünenthal has been operating in Santiago de Chile for 45 years.
The company’s largest manufacturing investment in the past three
decades, a new 3,500-square-meter facility in Chile, will enable a
production capacity of up to 1.8 billion tablets annually. This
facility's state-of-the-art technology reinforces Grünenthal's
position as Chile's leading pharmaceutical manufacturer.
Additionally, the advanced technology will positively impact
employees by providing training and specialization, positioning them
at the forefront of the industry. Grünenthal aims to complete the
certification process with the European Medicines Agency (EMA) by
November 2025, enabling the supply of medicines from Chile to Europe.
Grünenthal's manufacturing site in Quito, Ecuador, is one of the
few in Latin America licensed to export to Europe and the only one in
Ecuador with an EU Good Manufacturing Practice certificate, setting a
high industry standard. The 50,000-square-metre campus is Ecuador's
largest and most modern manufacturing plant for solid, semi-solid,
and liquid pharmaceuticals. Starting in 2025, the new facility will
produce up to 300 million high-quality tablets annually for pain
patients in 17 European countries.
About Grünenthal
Grünenthal is a global leader in pain management and related
diseases. As a science-based, fully integrated pharmaceutical
company, we have a long track record of bringing innovative
treatments and state-of-the-art technologies to patients worldwide.
Our purpose is to change lives for the better – and innovation is our
passion. We are focusing all our activities and efforts on working
towards our vision of a World Free of Pain.
Grünenthal is headquartered in Aachen, Germany, and has affiliates
in 27 countries across Europe, Latin America, and the U.S. Our
products are available in approx. 100 countries. In 2023, Grünenthal
employed around 4,400 people and achieved revenues of €1.8 billion.
More information:
https://www.grunenthal.com
(
https://www.grunenthal.com) and [Grünenthal Report 2023/24]
(
https://grunenthal-annualreport23.corporate-report.net/#0)
Follow us on:
LinkedIn: [Grünenthal Group]
(
https://eur03.safelinks.protection.outlook.com/?url=https%3A%2F%2Fww
w.linkedin.com%2Fcompany%2Fgruenenthal%3ForiginalSubdomain%3Dde&data=
05%7C02%7CAlexandra.Paesch%40grunenthal.com%7C148c5efb478543e5a69f08d
c4ca678ad%7C1aa3f19739d54269bcea93372aa086d9%7C0%7C0%7C63846952507246
3320%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJB
TiI6Ik1haWwiLCJXVCI6Mn0%3D%7C0%7C%7C%7C&sdata=SrmoYmZOKJUHShIZzqjf2vI
iqyrf5AT%2BxR924ZoSlfY%3D&reserved=0)
Instagram: [Grünenthal]
(
https://eur03.safelinks.protection.outlook.com/?url=https%3A%2F%2Fww
w.instagram.com%2Fgrunenthal%2F%3Fhl%3Dde&data=05%7C02%7CAlexandra.Pa
esch%40grunenthal.com%7C148c5efb478543e5a69f08dc4ca678ad%7C1aa3f19739
d54269bcea93372aa086d9%7C0%7C0%7C638469525072478288%7CUnknown%7CTWFpb
GZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn
0%3D%7C0%7C%7C%7C&sdata=O6riBAbMgpBu%2FRebEJkGl3c8h6hFk%2Bskpb%2FxUkG
uDFw%3D&reserved=0)
BSN Podcasts
Christian Drastil: Wiener Börse Plausch
Börsepeople im Podcast S14/11: Monika Kovarova-Simecek (Upd. 1)
Aktien auf dem Radar:Rosenbauer, FACC, CA Immo, Austriacard Holdings AG, Warimpex, Amag, Porr, Lenzing, Wienerberger, Bawag, DO&CO, EVN, voestalpine, Addiko Bank, ams-Osram, Marinomed Biotech, Oberbank AG Stamm, Flughafen Wien, Kapsch TrafficCom, Agrana, Erste Group, Immofinanz, Österreichische Post, S Immo, Telekom Austria, Uniqa, VIG, Nike, Wal-Mart, Rheinmetall, Deutsche Telekom.
Uniqa
Die Uniqa Group ist eine führende Versicherungsgruppe, die in Österreich und Zentral- und Osteuropa tätig ist. Die Gruppe ist mit ihren mehr als 20.000 Mitarbeitern und rund 40 Gesellschaften in 18 Ländern vor Ort und hat mehr als 10 Millionen Kunden.
>> Besuchen Sie 68 weitere Partner auf boerse-social.com/partner
Mehr aktuelle OTS-Meldungen HIER